15 November 2024 in Scandinavian Journal of Rheumatology
To investigate the function of mitophagy in instructing T-cell differentiation of patients with rheumatoid arthritis (RA). The mRNA and protein levels of optic atrophy protein-1 were detected in T cells from 94 RA patients and 37 age- and sex-matched healthy individuals by quantitative polymerase chain reaction and Western blotting. The impact of mitophagy on the differentiation of T cells was determined by flow cytometry. The therapeutic effect of targeting mitophagy was explored in humanized RA chimeras. Our study showed that T cells exerted high levels of mitophagy in RA patients. Since multiple T-cell subtypes play crucial roles in RA, we determined that mitophagy had a significant impact on the differentiation of tissue-resident memory T (Trm) cells, but not Th1 or Th17 cells. Importantly, we demonstrated that inhibiting mitophagy significantly reduced the number of Trm cells and downregulated inflammatory responses, as evidenced by diminished levels of T cell receptor β, interferon-γ, and interleukin-17A, in the humanized RA chimeras. Mitophagy is elevated in RA T cells, leading to maldifferentiation of Trm cells in RA patients. Since these findings were obtained from clinical patients, mitophagy may be a potential therapeutic target for RA treatment.
1 August 2023 in Aging Cell
24 October 2025 in Medicine
Rationale: Platelet transfusions are the key treatment for patients with severely low platelet counts and significant bleeding symptoms. Platelet transfusion refractorines (PTR) is defined as unsatisfactory transfusion of platelets with at least 2 ABO blood groups matched and stored for <72 hours. Patient concerns: A 37-year-old woman presented for medical evaluation due to the cessation of fetal heart activity after 50 days of gestation. Diagnoses: AML-M2, PTR. Interventions: To explore potential immune-mediated causes of platelet refractoriness, the following diagnostic evaluations were conducted: Platelet antibody screening using the PAK-Lx assay (Immucor) to detect anti-HLA class I and HPA antibodies. Anti-HLA class I specificity determination via LIFECODES LSA Single Antigen bead assays (Luminex). Molecular typing of HLA class I and HPA alleles using PCR-sequence based typing (PCR-SBT), as well as CD36 phenotyping via flow cytometry. Confirmation testing for anti-HPA-5b antibodies using chloroquine-treated platelet solid-phase assays. Outcomes: The patient had high-fluorescence-intensity HLA antibodies along with HPA antibodies, resulting in severe refractoriness to platelet transfusion. Lessons: Various methods were used to comprehensively analyze the specificity of anti-platelet antibodies in the samples of patients with ineffective platelet transfusion, thus providing a reference for the clinical diagnosis and treatment of PTR.